The SAB will provide clinical and scientific expertise to help the Company advance its pipeline and leverage its proprietary silence and replace THRIVE™ platform.
Apic’s CEO, John Reilly, MS/MBA, stated, "As we continue to advance our programs, it is critical that we obtain input from individuals with diverse expertise across a broad range of relevant research and development areas. The formation of our SAB represents another important step forward for the company. We are honored to welcome such an esteemed group of clinicians and researchers who have been at the forefront of gene therapy translational medicine.”
The appointments to Apic’s Scientific Advisory Board include:
Robert H. Brown Jr, DPhil, MD, Leo P. and Theresa M. LaChance Chair in Medical Research, Professor of Neurology, Director of the Program in Neurotherapeutics, University of Massachusetts Medical School
R. Jude Samulski, PhD, President, Chief Scientific Officer and Co-Founder at AskBio
Barry Byrne, MD, PhD, Director of the Powell Gene Therapy Center at the University of Florida and Professor of Pediatrics and Molecular Genetics & Microbiology
Rob Kotin, PhD, Adjunct Professor at University of Massachusetts Medical School
Kevin Flanigan, MD, Robert F. and Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research and Director of the Center for Gene Therapy in The Abigail Wexner Research Institute at Nationwide Children's Hospital, and Professor of Pediatrics and Neurology at The Ohio State University College of Medicine
Mark Kay, MD, PhD, Dennis Farrey Family Professor in Pediatrics and Professor of Genetics at Stanford University School of Medicine
SAB member biographies are available at http://www.apic-bio.com/
About Apic Bio
Apic Bio is an innovative gene therapy company focused on developing first-in-class treatment options for rare, undertreated neurological and liver diseases. The Company's lead program is an adeno-associated (AAV)-based gene therapy for the treatment of the copper zinc superoxide dismutase 1 (SOD1) genetic form ALS. Preclinical studies of additional genetic forms of ALS (C9Orf72) and Alpha-1 Antitrypsin Deficiency (Alpha-1) are ongoing. The Company is also advancing discovery programs for two undisclosed CNS indications that leverage its proprietary silence and replace THRIVE™ platform. The Company is backed by leading and disease-centric investors, including Morningside Ventures, ALS Investment Fund, and The Alpha-1 Project (TAP). For more information please visit www.apic-bio.com.